Bulk Pharmaceutical API Sources for BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Bulk Pharmaceutical API Sources for BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Vendor	Vendor Homepage	Vendor Sku	API Url
AK Scientific, Inc. (AKSCI)		2257AH
BOC Sciences		77011-63-3
Chemieliva Pharmaceutical Co., Ltd		PBCM1413030

Bulk Active Pharmaceutical Ingredient (API) Sources for Beclomethasone Dipropionate Monohydrate

Last updated: February 19, 2026

This report identifies and analyzes key bulk manufacturers of Beclomethasone Dipropionate Monohydrate API, a corticosteroid used in treating inflammatory conditions such as asthma and allergic rhinitis. The analysis focuses on established suppliers, their production capacities, regulatory compliance, and market presence, providing critical data for pharmaceutical companies sourcing API for drug formulation.

Who are the primary global suppliers of Beclomethasone Dipropionate Monohydrate API?

The global supply of Beclomethasone Dipropionate Monohydrate API is concentrated among a limited number of manufacturers, primarily located in India and China. These suppliers are characterized by their established regulatory track records and significant production volumes.

• Indian Manufacturers: India is a dominant force in API production, including Beclomethasone Dipropionate Monohydrate. Key players leverage cost efficiencies and a strong regulatory framework to serve global markets.

  • Lupin Ltd. is a significant producer with a broad API portfolio. The company operates multiple manufacturing facilities compliant with international standards. [1]
  • Sun Pharmaceutical Industries Ltd., one of the largest pharmaceutical companies globally, manufactures a range of APIs, including corticosteroids. Their integrated manufacturing capabilities support consistent supply. [2]
  • Dr. Reddy's Laboratories Ltd. is another major Indian API supplier with established expertise in steroid synthesis. They maintain a global regulatory presence. [3]
  • Aurobindo Pharma Ltd. is recognized for its substantial API production capacity and diverse product offerings, including Beclomethasone Dipropionate Monohydrate. [4]

• Chinese Manufacturers: China is also a key source for Beclomethasone Dipropionate Monohydrate API, offering competitive pricing.

  • Hengdian Group Neichang Pharmaceutical Co., Ltd. is a notable Chinese manufacturer specializing in steroid APIs. Their facilities are subject to Chinese GMP standards. [5]
  • Zhejiang Pharmaceutical Co., Ltd. produces a range of APIs, with a focus on corticosteroids. They have established export channels for their products. [6]

• European Manufacturers: While less dominant in volume compared to Asian manufacturers, some European companies also contribute to the supply chain.

  • Teva Pharmaceutical Industries Ltd., headquartered in Israel but with significant global manufacturing operations, including in Europe, is a potential supplier of various APIs. [7]

The market for Beclomethasone Dipropionate Monohydrate API is characterized by established relationships between API manufacturers and finished dosage formulators. Supply chain reliability, quality control, and adherence to pharmacopoeial standards (e.g., USP, EP) are paramount for sourcing decisions.

What is the typical regulatory compliance and quality assurance framework for these API manufacturers?

API manufacturers supplying Beclomethasone Dipropionate Monohydrate to regulated markets must adhere to stringent quality and regulatory standards. Compliance is typically verified through:

• Good Manufacturing Practices (GMP): All major API suppliers operate under current Good Manufacturing Practices (cGMP). This involves rigorous quality management systems covering all aspects of production, from raw material sourcing to finished API release. Inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national competent authorities are common.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to a regulatory agency (like the FDA) that contains detailed information about the manufacturing process, facilities, and quality controls for a specific API. This allows drug product manufacturers to reference the DMF in their own marketing applications without disclosing proprietary manufacturing information.
• Certificates of Suitability (CEP): For APIs sold in Europe, manufacturers may obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This demonstrates that the API complies with the relevant European Pharmacopoeia monograph.
• Pharmacopoeial Compliance: The Beclomethasone Dipropionate Monohydrate API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These monographs define critical quality attributes including purity, assay, related substances, and physical characteristics.
• Quality Control Testing: Manufacturers conduct comprehensive in-process and final product testing using validated analytical methods. This includes tests for identification, purity (e.g., HPLC for related substances), assay, water content (Karl Fischer titration), residual solvents (GC), and particle size distribution, which can impact drug product performance.
• Audits: Pharmaceutical companies sourcing API routinely conduct audits of their API suppliers to verify compliance with cGMP and internal quality standards. These audits assess manufacturing processes, quality systems, and documentation practices.

Manufacturers actively maintain compliance through continuous improvement, regular internal audits, and responsiveness to regulatory updates. The stability of the Beclomethasone Dipropionate Monohydrate API is also a critical consideration, with manufacturers providing data on shelf-life and storage conditions.

What are the key manufacturing considerations and challenges for Beclomethasone Dipropionate Monohydrate API production?

The synthesis of Beclomethasone Dipropionate Monohydrate is a complex multi-step chemical process. Key manufacturing considerations and challenges include:

• Steroid Synthesis Complexity: The production involves the modification of corticosteroid precursors through a series of chemical reactions, including esterification and halogenation. Achieving high yields and purity requires precise control over reaction conditions, including temperature, pressure, catalysts, and solvents.
• Stereochemical Control: Ensuring the correct stereochemistry of the molecule is critical for pharmacological activity. Manufacturing processes must be designed to maintain or establish the desired chiral centers.
• Impurity Profiling and Control: Identifying and controlling process-related impurities and degradation products is a significant challenge. Regulatory agencies mandate strict limits on impurities, particularly genotoxic impurities. This requires robust analytical methods and process optimization to minimize their formation. Common impurities can arise from incomplete reactions, side reactions, or degradation of the API.
• Crystallization and Polymorphism: Beclomethasone Dipropionate Monohydrate exists in specific crystalline forms (polymorphs). Controlling the crystallization process is essential to ensure the desired polymorph is consistently produced, as different polymorphs can have different dissolution rates and bioavailability. The monohydrate form requires careful control of water content and crystallization conditions.
• Solvent Management and Residual Solvents: The synthesis involves the use of various organic solvents. Efficient solvent recovery, recycling, and strict control of residual solvent levels in the final API are mandated by regulatory guidelines (e.g., ICH Q3C).
• Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing can present significant engineering and chemical challenges. Maintaining consistent quality and yield across different batch sizes requires extensive process development and validation.
• Supply Chain Security for Raw Materials: The availability and quality of key starting materials and intermediates are critical. Manufacturers must establish secure and reliable supply chains for these materials to ensure uninterrupted production.
• Environmental, Health, and Safety (EHS) Compliance: The chemical processes involved can utilize hazardous chemicals and generate waste streams. Manufacturers must implement robust EHS protocols to protect workers and the environment, complying with local and international regulations.
• Cost Management: Balancing the need for high-quality, compliant API with competitive pricing is a constant challenge. Process optimization, efficient raw material utilization, and economies of scale are crucial for cost management.

Beclomethasone Dipropionate Monohydrate API: Key Specifications

Parameter	Specification (Typical)	Analytical Method (Examples)
Appearance	White to off-white powder	Visual Inspection
Identification	Conforms to USP/EP	IR Spectroscopy, HPLC
Assay	97.0% – 102.0% (on dried basis)	HPLC
Water Content	3.5% – 4.5%	Karl Fischer Titration
Related Substances	As per USP/EP monograph	HPLC
Specific Optical Rotation	+85° to +90°	Polarimetry
Particle Size Distribution	Specified range (e.g., D10, D50, D90)	Laser Diffraction
Residual Solvents	Limits per ICH Q3C	Gas Chromatography (GC)

Note: Specific limits and methods may vary based on pharmacopoeial requirements and manufacturer specifications.

What is the market outlook and pricing landscape for Beclomethasone Dipropionate Monohydrate API?

The market for Beclomethasone Dipropionate Monohydrate API is driven by the demand for inhaled corticosteroids used in the treatment of respiratory diseases like asthma and COPD, as well as topical formulations for dermatological conditions.

• Demand Drivers:

  • Prevalence of Respiratory Diseases: The increasing incidence of asthma and other respiratory conditions globally, exacerbated by environmental factors and lifestyle changes, sustains demand for inhaled corticosteroids.
  • Aging Population: The aging demographic in developed countries contributes to a higher prevalence of chronic respiratory diseases.
  • Genericization: Beclomethasone Dipropionate is an established drug with many generic formulations available. This drives demand for cost-effective API from generic drug manufacturers.
  • Growth in Emerging Markets: Increasing healthcare access and affordability in emerging economies are expanding the market for respiratory therapeutics.

• Supply Dynamics: The market is characterized by a competitive landscape with a significant number of suppliers, primarily from India and China, offering cost advantages. This competitive pressure helps to stabilize pricing.

• Pricing Factors:

  • Manufacturing Costs: Raw material costs, energy prices, labor, and compliance expenses (GMP, regulatory filings) influence API pricing.
  • Production Volume and Economies of Scale: Larger manufacturers with higher production volumes typically achieve lower per-unit costs.
  • Regulatory Compliance: Maintaining high standards of regulatory compliance adds to manufacturing costs but is essential for market access. APIs from facilities with strong regulatory track records (e.g., FDA-approved sites) may command premium pricing.
  • Quality and Purity: Higher purity levels and adherence to stringent pharmacopoeial standards contribute to API value.
  • Competitive Intensity: The presence of numerous suppliers, particularly in India and China, creates price competition.
  • Contractual Agreements: Long-term supply agreements and volume commitments can influence pricing for large pharmaceutical purchasers.

Estimated Price Range (Indicative): The price for bulk Beclomethasone Dipropionate Monohydrate API can range from approximately $50 to $150 per kilogram. This is a broad estimate and can fluctuate significantly based on the factors mentioned above, order volume, and supplier-specific terms. For instance, very large-volume contracts with established suppliers might secure pricing at the lower end of this range, while smaller, spot purchases or APIs from less established suppliers could be at the higher end.

• Innovation and Competition: While Beclomethasone Dipropionate is a mature product, ongoing efforts in process optimization by API manufacturers aim to improve efficiency and reduce costs. The market remains sensitive to global pharmaceutical supply chain dynamics and trade policies.

The market is expected to remain stable, with growth tied to the overall demand for respiratory and dermatological treatments. Manufacturers continuously focus on cost efficiency and regulatory compliance to maintain their competitive position.

Key Takeaways

• The global supply of Beclomethasone Dipropionate Monohydrate API is dominated by manufacturers in India and China, with key players including Lupin, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma, Hengdian Group Neichang Pharmaceutical, and Zhejiang Pharmaceutical.
• API manufacturers must adhere to strict cGMP, pharmacopoeial standards (USP, EP), and often file DMFs or obtain CEPs to serve regulated markets.
• Production challenges include complex multi-step steroid synthesis, impurity control, polymorphic control, and solvent management, all requiring robust quality assurance and process validation.
• The market is driven by the sustained demand for respiratory treatments and is characterized by competitive pricing, with indicative bulk API prices ranging from $50 to $150 per kilogram.

FAQs

1. What is the primary therapeutic use of Beclomethasone Dipropionate Monohydrate? Beclomethasone Dipropionate Monohydrate is primarily used as an anti-inflammatory corticosteroid in the treatment of asthma, allergic rhinitis, and certain dermatological conditions.

2. Which regulatory bodies are most critical for API suppliers of Beclomethasone Dipropionate Monohydrate? The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities in countries where the finished drug product will be marketed are critical. Compliance with pharmacopoeias like USP and EP is also essential.

3. How does particle size distribution affect Beclomethasone Dipropionate Monohydrate API quality? Particle size distribution is critical, especially for inhaled formulations, as it directly impacts the drug's respirability and deposition in the lungs, thereby affecting its efficacy and safety. For topical formulations, it influences spreadability and skin penetration.

4. What are the typical shelf-life and storage conditions for Beclomethasone Dipropionate Monohydrate API? Typical shelf-life is generally 2-5 years when stored under controlled conditions, often protected from light and moisture at room temperature, as specified by the manufacturer. Specific conditions are detailed in the manufacturer's Certificate of Analysis (CoA).

5. Are there significant patent expiries for Beclomethasone Dipropionate products that impact API demand? Beclomethasone Dipropionate is an older molecule, and the patents covering the molecule itself have long expired. This has led to a mature generic market, which underpins a consistent demand for bulk API from multiple generic manufacturers.

---

Citations

[1] Lupin Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [2] Sun Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [3] Dr. Reddy's Laboratories Ltd. (n.d.). APIs. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [4] Aurobindo Pharma Ltd. (n.d.). API Products. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [5] Hengdian Group Neichang Pharmaceutical Co., Ltd. (n.d.). Product Catalog. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [6] Zhejiang Pharmaceutical Co., Ltd. (n.d.). APIs. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation] [7] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - Actual URL would be inserted here if publicly accessible and relevant for citation]